Loading...
Market
Story
Amgen's Imdelltra for Advanced Lung Cancer Wins Accelerated US Approval
May 16, 2024, 07:09 PM
Amgen has received US FDA accelerated approval for its new drug, Imdelltra, designed to treat adult patients with advanced small cell lung cancer. The approval, granted on May 16, 2024, marks a significant step in the fight against this particularly aggressive form of cancer. The drug, also known as tarlatamab, is a targeted immunotherapy aimed at patients whose condition has worsened despite chemotherapy.
View original story
Similar markets
<10% • 25%
10%-25% • 25%
26%-50% • 25%
>50% • 25%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
EU only • 25%
UK only • 25%
Japan only • 25%
Multiple regions including EU, UK, and Japan • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
No further action • 33%
Additional warnings issued • 33%
Restriction on use broadened • 33%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Less than 5% • 33%
5% to 15% • 33%
More than 15% • 34%